Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-24-0515
Abstract: Abstract Inhibition of the deubiquitinating enzyme USP1 can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD) and represents a novel therapeutic strategy for the treatment of BRCA1/2-mutant cancers, potentially including patients whose… read more here.
Keywords: tng348 parpi; recombination deficiency; tng348; homologous recombination ... See more keywords